A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

You could also try: marks (231), results (1000)

WRES report and action plan 2023

Description
Workforce Race Equality Standard Annual Report 2023 1 Table of Contents Executive Summary........................
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Equality-reports/WRES-report-and-action-plan-2023.pdf

Workforce Race Equality Standard Annual Report 2022

Description
Workforce Race Equality Standard - Annual Report 2022 Table of Contents Executive Summary
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Equality-reports/Workforce-Race-Equality-Standard-Annual-Report-2022.docx

Gemcitabine (21day) ver1.1

Description
Chemotherapy Protocol BLADDER GEMCITABINE (21 day) Regimen Bladder-Gemcitabine Indication Locally advanced or metastatic urothelial cancer in patients unsuitable for cisplatin
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Gemcitabine-21day-ver1.1.pdf

Enzalutamide

Description
Chemotherapy Protocol PROSTATE ENZALUTAMIDE Regimen • Prostate-Enzalutamide Indication • Enzalutamide is recommended within its marketing authorisation as an option for treating metastatic
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Prostatecancer/Enzalutamide.pdf

Docetaxel (30)-Prednisolone ver1.1

Description
Chemotherapy Protocol PROSTATE DOCETAXEL(30)-PREDNISOLONE Regimen Prostate-Docetaxel (30)-Prednisolone Indication Advanced castrate resistant prostate cancer Performance status 0, 1
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Prostatecancer/Docetaxel-30-Prednisolone-ver1.1.pdf

RPACEBOM - Bleomycin-Cyclophosphamide-Doxorubicin-Etoposide-Methotrexate-Prednisolone-Rituximab-Vincristine

Description
Chemotherapy Protocol LYMPHOMA BLEOMYCIN-CYCLOPHOSPHAMIDE-DOXORUBICIN-ETOPOSIDE-METHOTREXATEPREDNISOLONE-RITUXIM
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/RPACEBOM-Bleomycin-Cyclophosphamide-Doxorubicin-Etoposide-Methotrexate-Prednisolone-Rituximab-Vincristine.pdf

Rituximab (weekly)

Description
Chemotherapy Protocol LYMPHOMA RITUXIMAB (weekly) Regimen Lymphoma – Rituximab (weekly) Indication CD20 positive indolent non Hodgkin’s lymphoma. Toxicity Drug Rituxumab Adverse
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Rituximab-weekly.pdf

Rituximab (3 weekly)

Description
Chemotherapy Protocol LYMPHOMA RITUXIMAB (3 Weekly) Regimen Lymphoma – Rituximab (3 weekly) Indication Non Hodgkin’s Lymphoma in combination with chemotherapy Toxicity
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Rituximab-3-weekly.pdf

REPOCH (dose adjusted)-Cyclophosphamide-Doxorubicin-Etoposide-Prednisolone-Rituximab-Vincristine

Description
Chemotherapy Protocol LYMPHOMA REPOCH - CYCLOPHOSPHAMIDE-DOXORUBICIN-ETOPOSIDE-PREDNISOLONERITUXIMAB-VINCRISTINE (Dose
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/REPOCH-dose-adjusted-Cyclophosphamide-Doxorubicin-Etoposide-Prednisolone-Rituximab-Vincristine.pdf

InP-REPOCH-Cyclophosphamide-Doxorubicin-Etoposide-Prednisolone-Rituximab-Vincristine

Description
Chemotherapy Protocol LYMPHOMA REPOCH - CYCLOPHOSPHAMIDE-DOXORUBICIN-ETOPOSIDE-PREDNISOLONERITUXIMAB-VINCRISTINE (In-Patient
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/InP-REPOCH.pdf
371 to 380 of 548
Previous … 36 37 38 39 40 … Next